News tagged with paclitaxel

Related topics: breast cancer , cancer , cancer cells , chemotherapy , ovarian cancer

New hope for taming triple-negative breast cancer

Disease-free survival is short-lived for women with triple-negative breast cancer—a form of the disease that doesn't respond to hormone drugs and becomes resistant to chemotherapy. Thankfully, a promising ...

Oct 02, 2012
popularity 4.3 / 5 (3) | comments 0

Whole genome or exome sequencing: An individual insight

Focusing on parts rather than the whole, when it comes to genome sequencing, might be extremely useful, finds research in BioMed Central's open access journal Genome Medicine. The research compares several sequencing techno ...

Jun 27, 2013
popularity 5 / 5 (2) | comments 0 | with audio podcast

Combination therapy may enhance gemcitabine activity

Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Di ...

Feb 28, 2012
popularity 3 / 5 (2) | comments 0

Optimal dose suggested for dasatinib in ovarian cancer

(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, ...

Nov 19, 2012
popularity 5 / 5 (1) | comments 0

Two-drug combination may slow deadly thyroid cancer

A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine. The two drugs togeth ...

Jan 08, 2013
popularity 5 / 5 (1) | comments 0 | with audio podcast

Good long-term outcomes for drug-eluting stents

(HealthDay) -- Meta-analysis of randomized clinical trials (RCTs) suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, ...

Apr 04, 2012
popularity 4 / 5 (1) | comments 0 | with audio podcast

Medication duloxetine helps reduce pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April ...

Apr 02, 2013
popularity 4 / 5 (1) | comments 0

Paclitaxel

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a U.S. National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to paclitaxel and the BMS compound is sold under the trademark TAXOL. In this formulation, paclitaxel is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.

Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.

Paclitaxel stabilizes microtubules and as a result, interferes with the normal breakdown of microtubules during cell division. Together with docetaxel, it forms the drug category of the taxanes. It was the subject of a notable total synthesis by Robert A. Holton.

While offering substantial improvement in patient care, paclitaxel has been a relatively controversial drug. There was originally concern because of the environmental impact of its original sourcing, no longer used, from the Pacific yew. In addition, the assignment of rights, and even the name itself, to Bristol-Myers Squibb were the subject of public debate and Congressional hearings.

This text uses material from Wikipedia licensed under CC BY-SA